Evidence map›Paper›PMID 31905251›Full record

ArticleCancer2020

Genomic and clinical characterization of stromal infiltration markers in prostate cancer.

Brandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, Himisha Beltran, William S Chen, Fallon Chipidza, Elai Davicioni, R Jeffrey Karnes, Sheng-Yu Ku, Tamara L Lotan and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Brandon A MahalDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0003-3036-334X
Mohammed AlshalalfaDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Shuang G ZhaoUniversity of Michigan, Ann Arbor, Michigan.
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
William S ChenUniversity of California at San Francisco, San Francisco, California.ORCID 0000-0002-3717-670X
Fallon ChipidzaDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Elai DavicioniGenomeDx, Inc, San Diego, California.
R Jeffrey KarnesMayo Clinic, Rochester, Minnesota.
Sheng-Yu KuDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Tamara L LotanJohns Hopkins Medical Institutions, Baltimore, Maryland.
Vinayak MuralidharDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Timothy R RebbeckDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Edward M SchaefferNorthwestern University, Chicago, Illinois.
Daniel E SprattUniversity of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-5973-4741
Felix Y FengUniversity of California at San Francisco, San Francisco, California.
Paul L NguyenDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Brigham and Women's Hospital · USUniversity of California, San Francisco · USUniversity of Michigan · USGenomatica (United States) · USJohns Hopkins University · USMayo Clinic · USNorthwestern University · US

Funding

Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
NCI NIH HHS P20 CA233255
6 · The paper itself

Abstract

backgroundThe progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.

methodsGenome-wide expression profiles of formalin-fixed, paraffin-embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135). Two independent stromal gene expression signatures implied stromal infiltration. Cox proportional hazards regression defined the association between stromal infiltration expression and metastasis-free survival (MFS).

resultsStromal expression scores were correlated with stromal signature genes and with other key stromal markers (CAV1, VIM, and TAGLN), basal activity, and CD3 and CD4 immune biomarkers (r > 0.5 for all). The top decile of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6) , high Cancer of the Prostate Risk Assessment-Postsurgical scores, Gleason 9 to 10 disease, and a higher risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37-4.02; P = .001). A higher stromal infiltration score was also associated with decreased expression of DNA repair genes and higher radiation sensitivity genomic scores. Postoperative radiation therapy (RT) was associated with an MFS benefit for patients with high stromal scores, but not for patients with low stromal scores (P

conclusionsExpression of stromal infiltration markers is correlated with prostate cancer aggressiveness/progression and may be predictive of a response to RT. Stromal infiltration markers should be studied and considered for incorporation into clinical prognostication and decision making.

Indexed as

AgedBiomarkers, TumorCohort StudiesHumansMaleMiddle AgedProstatic NeoplasmsTranscriptomeTumor MicroenvironmentBiomarkers, TumorDeciphergenomicsprostatic neoplasmsstromal infiltrationtumor microenvironment

Identifiers

PMID31905251
PMCPMC7332205
OpenAlexW3000400923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.